← Eichor
Condition: Merkel Cell Carcinoma Of Skin Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Merkel Cell Carcinoma Of Skin

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Personalised Immunotherapy Platform
Phase N/A · 3 location(s) · Melanoma Institute Australia · NCT06536257
Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06780475
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05859074
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr
Phase 2 · 1 location(s) · Mayo Clinic · NCT07285044
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metasta
Phase 1/Phase 2 · 26 location(s) · National Cancer Institute (NCI) · NCT05896839
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 · 2 location(s) · Memgen, Inc. · NCT05076760
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histo
NA · 1 location(s) · Istituto Oncologico Veneto IRCCS · NCT06753136
A Study of VET3-TGI in Patients With Solid Tumors
Phase 1 · 7 location(s) · KaliVir Immunotherapeutics · NCT06444815
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · AstraZeneca · NCT07115043
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/Phase 2 · 7 location(s) · Neonc Technologies, Inc. · NCT06047379
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626
A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692
TIL Therapy in cSCC and MCC
Phase 2 · 1 location(s) · Karam Khaddour, MD, MS · NCT07288073
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced
Phase 2/Phase 3 · 18 location(s) · TuHURA Biosciences, Inc. · NCT06947928
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381
French National Database of Rare Dermatological Cancers
Phase N/A · 34 location(s) · University Hospital, Lille · NCT03210935
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Select
Phase 1 · 2 location(s) · Kupando GmbH · NCT07600476
Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT02471352
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigra
Phase 2 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT06223659
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.